RUNX3 and hepatocellular carcinoma: An analysis of 108 clinical samples of hepatocellular carcinoma showed that miR-106b-5p, which is upregulated in hepatocellular carcinoma, exerted a pro-cancer effect through the inhibition of RUNX3, and that the targeting of RUNX3 by miR-106b-5p resulted in its decreased expression in tumor tissues [90].